PAVmed Appoints Industry Veteran Joseph Virgilio to Lead Relaunched Medical Device Portfolio

Virgilio to oversee development and commercialization of PAVmed's current and future medical device programs.

Apr. 2, 2026 at 12:40pm

Got story updates? Submit your updates here. ›

PAVmed Inc., a diversified commercial-stage medical technology company, has appointed Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to lead the relaunch and expansion of its medical device portfolio. Virgilio brings over 25 years of leadership experience in the medical device industry and will oversee the advancement of PAVmed's existing programs, including the PortIO implantable vascular access device and newly licensed endoscopic esophageal imaging technology, while also seeking to grow the pipeline with additional high-potential opportunities.

Why it matters

The appointment of an experienced industry veteran like Joseph Virgilio signals PAVmed's commitment to revitalizing its medical device business and pursuing a disciplined, capital-efficient growth strategy. Virgilio's track record of building and scaling successful medical technology companies will be crucial as PAVmed looks to advance its current portfolio and expand into new areas that can drive long-term shareholder value.

The details

Under Virgilio's leadership, PAVmed will relaunch its medical device portfolio, which includes the PortIO implantable vascular access device and newly licensed endoscopic esophageal imaging technology from Duke University. Virgilio will serve as CEO of the subsidiaries overseeing these programs, PortIO Inc. and Octeris Inc. PAVmed is also actively pursuing additional medical device opportunities, with a focus on synergies with its existing assets, including promising gastroesophageal reflux-focused technologies.

  • PAVmed and Duke University recently executed a definitive license agreement for the endoscopic esophageal imaging technology.
  • Virgilio most recently served as President and CEO of Morphic Medical, where he led the company's commercial and operational strategy and secured over $40 million in capital.

The players

Joseph Virgilio

A medical technology industry veteran with over 25 years of leadership experience, who has been appointed as Senior Vice President and Chief Business Officer, Medical Devices at PAVmed to oversee the development and commercialization of the company's medical device portfolio.

Lishan Aklog, M.D.

The Chairman and Chief Executive Officer of PAVmed, who stated that Virgilio's appointment will allow the company to leverage his deep sector experience and leadership as it advances its existing medical device programs and seeks to expand its pipeline.

PAVmed Inc.

A diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, which has relaunched its medical device portfolio under Virgilio's leadership.

Octeris, Inc.

A newly formed PAVmed subsidiary that will support ongoing sponsored research with Duke University to advance the development and clinical application of the licensed endoscopic esophageal imaging technology.

PortIO Inc.

A PAVmed subsidiary that oversees the development of the company's PortIO implantable intraosseous vascular access device.

Got photos? Submit your photos here. ›

What they’re saying

“Fixing PAVmed's capital structure and strengthening our balance sheet has allowed us to proceed with the long-anticipated relaunch our medical device portfolio under dedicated, experienced leadership.”

— Lishan Aklog, M.D., Chairman and Chief Executive Officer, PAVmed

“PAVmed has already established a strong foundation with its existing medical device programs, and I'm excited to build on that momentum. We have the opportunity to advance these assets while expanding the portfolio with additional high-quality opportunities.”

— Joseph Virgilio, Senior Vice President and Chief Business Officer, Medical Devices, PAVmed

What’s next

PAVmed is actively pursuing additional medical device opportunities across various subsectors, with a focus on those with synergies to existing assets, including promising gastroesophageal reflux-focused technologies.

The takeaway

The appointment of Joseph Virgilio, an experienced medical device industry veteran, to lead PAVmed's relaunched medical device portfolio signals the company's commitment to revitalizing this business segment and pursuing a disciplined, capital-efficient growth strategy. Virgilio's track record of building and scaling successful medical technology companies will be crucial as PAVmed looks to advance its current programs and expand into new high-potential areas.